AMENDMENTS TO THE CLAIMS

1.-12. (Cancelled)

13. (Currently Amended) A method for treating an infectious disease comprising administering to a subject in need thereof ~~and who is HIV-negative~~ a composition comprising ~~an agent~~ compound of Formula III [[I]] in an amount effective ~~amount~~ to inhibit progression of the infectious disease, and a pharmaceutically acceptable carrier,

wherein the ~~agent~~ compound of Formula III [[I]] is administered by injection or in an enterically coated form, and wherein the compound ~~agent~~ of Formula III [[I]] is:



wherein ~~Am and A_1 are L- or D- amino acid residues,~~ m is an integer between 0 and 10, inclusive; A is an L- or D-amino acid residue such that each A in [[Am]] A_m may be an amino acid residue different from another or all other A in [[Am]] A_m; the C bonded to B is in the L-configuration; and each X_1 and X_2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH; ~~A_1 is bonded to the R with a C bond that is in the L-configuration; and R is an organo-boronate, organo-phosphonate, fluoroalkylketone, alphaketo moiety, N-peptidyl-O-(acylhydroxylamine), azapeptide, azetidine, fluoroolefin, dipeptide isoestere, peptidyl (alpha-aminoalkyl) phosphonate ester, aminoacyl pyrrolidine-2-nitrile or 4-cyanothiazolidide, provided that R reacts with a functional group in the reactive site of (FAP-α) or other post-proline-cleaving enzyme, and~~

wherein after administration the ~~agent~~ compound is present in the subject at a serum concentration above 10^{-8} M, and wherein the infectious disease is not HIV infection.

14-163. (Cancelled)

164. (Previously Presented) A method of ~~preventing an infectious disease in a subject at risk of developing an infectious disease~~ reducing the probability that a subject will develop an infectious disease comprising

identifying a subject at risk of developing an infectious disease ~~and who is HIV-negative~~, and

administering a composition comprising ~~an agent~~ compound of Formula III [[I]] in an amount effective to induce IL-1, and a pharmaceutically acceptable carrier,

wherein the ~~agent~~ compound of Formula III [[I]] is administered by injection or in an enterically coated form, and wherein the ~~agent~~ compound of Formula III [[I]] is:





wherein ~~Am and A_1 are L- or D- amino acid residues,~~ m is an integer between 0 and 10, inclusive; A is an L- or D-amino acid residue such that each A in [[Am]] A_m may be an amino acid residue different from another or all other A in [[Am]] A_m; the C bonded to B is in the L-configuration; and each X_1 and X_2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH; ~~A_1 is bonded to the R with a C bond that is in the L-configuration; and R is an organo boronate, organo phosphonate, fluoroalkylketone, alphaketo moiety, N-peptidyl-O-(acylhydroxylamine), azapeptide, azetidine, fluoroolefin, dipeptide isoestere, peptidyl (alpha-aminoalkyl) phosphonate ester, aminoacyl pyrrolidine-2-nitrile or 4-cyanothiazolidide, provided that R reacts with a functional group in the reactive site of (FAP-α) or other post proline-cleaving enzyme, and~~

wherein after administration the ~~agent~~ compound is present in the subject at a serum concentration above 10^{-8} M, and wherein the infectious disease is not HIV infection.

165-484. (Cancelled)

485. (Withdrawn and Previously Presented) The method of claim 13, further comprising administering to the subject an anti-microbial agent.

486. (Withdrawn and Previously Presented) The method of claim 485, wherein the anti-microbial agent is an anti-bacterial agent.

487. (Withdrawn and Previously Presented) The method of claim 485, wherein the anti-microbial agent is an anti-viral agent.

488. (Withdrawn and Previously Presented) The method of claim 485, wherein the anti-microbial agent is an anti-fungal agent.

489. (Withdrawn and Previously Presented) The method of claim 485, wherein the anti-microbial agent is an anti-parasitic agent.

490. (Withdrawn and Previously Presented) The method of claim 485, wherein the anti-microbial agent is an anti-mycobacterial agent.

491. (Withdrawn and Previously Presented) The method of claim 164, further comprising administering to the subject a microbial antigen.

492. (Withdrawn and Previously Presented) The method of claim 491, wherein the microbial antigen is a bacterial antigen.

493. (Withdrawn and Previously Presented) The method of claim 491, wherein the microbial antigen is a viral antigen.

494. (Withdrawn and Previously Presented) The method of claim 491, wherein the microbial antigen is a fungal antigen.

495. (Withdrawn and Previously Presented) The method of claim 491, wherein the microbial antigen is a mycobacterial antigen.

496. (Withdrawn and Previously Presented) The method of claim 491, wherein the microbial antigen is a parasitic antigen.

497.-500. (Cancelled)

501. (Currently Amended) The method of claim 13, wherein the ~~agent~~ compound of Formula [[I]] III is Ile-boroPro.

502. (Currently Amended) The method of claim 164, wherein the ~~agent~~ compound of Formula [[I]] III is Ile-boroPro.

503. (Previously Presented) The method of claim 13, wherein injection is subcutaneous injection.

504. (Previously Presented) The method of claim 164, wherein injection is subcutaneous injection.

505. (Previously Presented) The method of claim 13, wherein injection is intravenous injection, intramuscular injection, or intraperitoneal injection.

506. (Previously Presented) The method of claim 164, wherein injection is intravenous injection, intramuscular injection, or intraperitoneal injection.

507. (Withdrawn and Previously Presented) The method of claim 13, wherein the enterically coated form is a pill, a capsule or a tablet.

508. (Withdrawn and Previously Presented) The method of claim 164, wherein the enterically coated form is a pill, a capsule or a tablet.

509. (Previously Presented) The method of claim 13, wherein the effective amount is about 0.005 mg/kg to less than 1.0 mg/kg body weight per day.

510. (Previously Presented) The method of claim 164, wherein the effective amount is about 0.005 mg/kg to less than 1.0 mg/kg body weight per day.

511. (Currently Amended) The method of claim 13, wherein at least 96% of ~~the agents~~ compounds in the pharmaceutically acceptable carrier comprises a C bonded to B ~~A_1 bonded to the R with a C bond that is~~ in the L-configuration.

512. (Currently Amended) The method of claim 164, wherein at least 96% of ~~the agents~~ compounds in the pharmaceutically acceptable carrier comprises a C bonded to B ~~A_1 bonded to the R with a C bond that is~~ in the L-configuration.

513.-514. (Cancelled)

515. (Currently Amended) The method of claim 13, wherein the ~~agent~~ compound of Formula [[I]] III is administered in an amount that increases lymphoid tissue levels of IL-1, G-CSF or IL-8.

516. (Currently Amended) The method of claim 164, wherein the ~~agent~~ compound of Formula [[I]] III is administered in an amount that increases lymphoid tissue levels of IL-1, G-CSF or IL-8.

517. (Currently Amended) The method of claim 13, wherein the ~~agent~~ compound of Formula [[I]] III is administered in an amount that does not increase serum IL-1 levels.

518. (Currently Amended) The method of claim 164, wherein the ~~agent~~ compound of Formula [[I]] III is administered in an amount that does not increase serum IL-1 levels.

519. (Currently Amended) The method of claim 13, wherein the ~~agent~~ compound of Formula [[I]] III is administered at a concentration of greater than 10^{-8}M.

520. (Currently Amended) The method of claim 164, wherein the ~~agent~~ compound of Formula [[I]] III is administered at a concentration of greater than 10^{-8}M.